Day: July 22, 2025

From target discovery to trial optimization, bfLEAP™ empowers biopharma teams to predict therapeutic success with greater confidence In a $200B+ market crowded with black-box AI, BullFrog AI’s bfLEAP™ delivers what others can’t: biologically grounded, composition-aware analytics that guide smarter therapeutic decisions GAITHERSBURG, Md., July 22, 2025 (GLOBE NEWSWIRE) — BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the release of a new white paper titled “Why Drug Discovery Fails and How AI is Changing the Equation.” The publication offers a compelling critique of conventional...

Seasoned leaders bring deep expertise in neuroscience drug development, strategic growth, and corporate finance to support BioVie’s mission CARSON CITY, Nev., July 22, 2025 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the appointment of Amy S. Chappell, MD, FAAN, and Kameel D. Farag to its Board of Directors. “Amy and Kameel each bring an extraordinary combination of strategic vision, operational excellence, and hands-on experience developing and commercializing therapies in complex neurological and chronic diseases,” said Cuong Do, President and Chief Executive Officer (CEO) of BioVie Inc. “As BioVie continues to advance bezisterim...

Designation Allows for Direct, Expedited U.S. Government Procurement WICHITA, Kan., July 22, 2025 (GLOBE NEWSWIRE) — AgEagle Aerial Systems Inc. (NYSE: UAVS), a leading provider of advanced drone and aerial imaging solutions, is proud to announce that its eBee VISION is now Blue UAS certified. This designation comes just a week after the Company’s eBee TAC received Blue UAS certification. The Blue UAS certification makes the AgEagle drone eligible for procurement by the U.S. Department of Defense (DoD) and other federal agencies and recognizes the drone as compliant with security and performance standards required by the DoD. “This is very welcome news, and we are so proud that now the eBee VISION joins our eBee TAC on the Blue UAS Cleared list for the Department of Defense,” said Bill Irby, CEO of AgEagle Aerial Systems. “This...

Expanded U.S.-clinical research study shows strong results including increased fat loss, improved cravings control, and healthier body composition*‡ SALT LAKE CITY, July 22, 2025 (GLOBE NEWSWIRE) — LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced new results from its second human clinical study on the MindBody GLP-1 System™, revealing even more compelling outcomes across a broader participant base. When researchers combined data from the most recent clinical trial completed in April 2025, with findings from the initial trial conducted in fall 2024, the average increase of GLP-1 improved to over 200% – a significant rise from the previously reported 140%. GLP-1 is a critical hormone that supports...

SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, is pleased to invite investors to a webinar on July 24, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Calidi’s CEO, Eric Poma, Ph.D. Attendees will gain insights into Calidi’s pioneering approach to precision genetic medicine, enabled by its proprietary RedTail™ platform—an engineered, systemically delivered viral therapy designed to reach metastatic and difficult-to-treat tumors. The platform cloaks potent genetic payloads, such as IL-15 superagonist, within a human-derived envelope, allowing the virus...

Proceeds to primarily support MASH pipeline expansion and to refinance existing senior credit facility $350 million initial term loan funded at close and up to an additional $150 million available through 2027 Agreement also provides for the possibility of additional incremental facilities of up to $250 million of credit to support further strategic pipeline expansionCONSHOHOCKEN, Pa., July 22, 2025 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it has entered into a $500 million senior secured credit facility with funds managed by Blue Owl Capital (NYSE: OWL), a leading alternative asset manager, to primarily advance Madrigal’s pipeline to further extend its...

Company Applauds Signing of Genius Act into Law by President Trump MINNEAPOLIS, MN, July 22, 2025 (GLOBE NEWSWIRE) — SharpLink Gaming, Inc. (Nasdaq: SBET) (“SharpLink” or the “Company”), the world’s largest corporate holder of Ether (“ETH”) as its primary treasury reserve asset, today issued its weekly update on the Company’s ETH holdings and capital raised through its At-The-Market (“ATM”) facility during the week Monday, July 14, 2025 through Sunday, July 20, 2025. Key Highlights for the Week Ending July 20, 2025:ETH holdings rose to 360,807 ETH, up 29% from the previous week. 79,949 ETH were purchased, the highest weekly amount in the historical reporting periods. Average ETH purchase price for the week was $3,238. ETH Concentration rose to 3.06 – up 53% since the Company launched its digital treasury strategy, with...

Conference call and webcast to be held the same day at 8:00 AM ET BRADENTON, Fla., July 22, 2025 (GLOBE NEWSWIRE) — First Watch Restaurant Group, Inc. (NASDAQ: FWRG) (“First Watch” or the “Company”), the leading Daytime Dining concept serving breakfast, brunch and lunch, today announced that it plans to release its second quarter 2025 financial results on Tuesday, August 5, 2025, before the market opens. A conference call and webcast will follow at 8:00 AM ET, hosted by Chris Tomasso, Chief Executive Officer and President, and Mel Hope, Chief Financial Officer. Interested parties may listen to the conference call via any one of three options:Dial 201-389-0914, which will be answered by an operator Pre-register by entering your information at this Call Me™ link Join the webcast at https://investors.firstwatch.com/news-and-events/eventsThe...

URUMQI, China, July 22, 2025 (GLOBE NEWSWIRE) — Chanson International Holding (Nasdaq: CHSN) (the “Company” or “Chanson”), a provider of bakery, seasonal, and beverage products through its chain stores in China and the United States, today announced the opening of two new stores in Xinjiang’s most iconic tourist destinations: the International Grand Bazaar in Urumqi and the historic Old City of Kashgar. These new openings mark a significant milestone in Chanson’s ongoing strategy to integrate culinary excellence with cultural tourism, deepening the brand’s presence in tourist destinations in Xingjiang. Strategically situated in the heart of Urumqi’s International Grand Bazaar or Urumqi Grand Bazaar—a representation of regional heritage that recently recorded a high single-day peak of visitors—the new store features traditional...

SOUTH SAN FRANCISCO, Calif., July 22, 2025 (GLOBE NEWSWIRE) — Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it has entered into a collaboration with the U.S. Food and Drug Administration (FDA) to develop reference materials to improve regulatory standards and enhance analytical methods for ADC drug development. The collaboration will leverage Sutro’s cell-free XpressCF® technology to precisely engineer ADCs with predefined attributes, as well as FDA’s cutting-edge analytical capabilities to fully characterize these materials. “ADCs represent one of the most promising and fast-growing modalities for new biopharmaceuticals. We’re honored to be among a select group collaborating with the FDA to help shape...